ADMA — ADMA Biologics Share Price
Last Trade - 00:00- $170.49m
- $201.94m
- $48.07m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 10.66 | 22.76 | 16.99 | 29.35 | 42.22 | 71.97 | 113.36 | 42.53% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.
Directors
- Steven Elms (57)
- Adam Grossman PRE (44)
- Jerrold Grossman (73)
- Brian Lenz CFO (48)
- Martha Demski (68)
- Bryant Fong (48)
- Lawrence Guiheen (70)
- Last Annual
- December 31st, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- June 2nd, 2006
- Public Since
- October 17th, 2013
- No. of Shareholders
- 20,000
- No. of Employees
- 406
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 128,189,628
- Address
- C/O Adma Biologics, RAMSEY, 07446
- Web
- https://www.admabiologics.com/
- Phone
- +1 2014785552
- Auditors
- CohnReznick LLP
Latest News for ADMA
Upcoming events for ADMA
Q3 2021 ADMA Biologics Inc Earnings Release
Similar to ADMA
4D PHARMA ADR REP 8 ORD
NASDAQ Global Market
89BIO ORD
NASDAQ Global Market
ACCELERON PHARMA ORD
NASDAQ Global Market
ACELRX PHARMACEUTICALS ORD
NASDAQ Global Market
ADAGENE 4 ADR REP 5 ORD
NASDAQ Global Market
FAQ
As of Today at 19:56 UTC, shares in ADMA Biologics are trading at $1.33. This share price information is delayed by 15 minutes.
Shares in ADMA Biologics last closed at $1.33 and the price had moved by -57.37% over the past 365 days. In terms of relative price strength the ADMA Biologics share price has underperformed the S&P500 Index by -67.66% over the past year.
The overall consensus recommendation for ADMA Biologics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
ADMA Biologics does not currently pay a dividend.
ADMA Biologics does not currently pay a dividend.
ADMA Biologics does not currently pay a dividend.
To buy shares in ADMA Biologics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.33, shares in ADMA Biologics had a market capitalisation of $170.49m.
Here are the trading details for ADMA Biologics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ADMA
Shares are classified based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
ADMA Biologics does not currently have a style classification.
The analyst consensus target price for shares in ADMA Biologics is $7.40. That is 456.39% above the last closing price of $1.33.
Analysts covering ADMA Biologics currently have a consensus Earnings Per Share (EPS) forecast of -$0.57 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ADMA Biologics. Over the past six months, its share price has underperformed the S&P500 Index by -55.95%.
As of the last closing price of $1.33, shares in ADMA Biologics were trading -31.28% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for ADMA Biologics.
ADMA Biologics' management team is headed by:
- Steven Elms -
- Adam Grossman - PRE
- Jerrold Grossman -
- Brian Lenz - CFO
- Martha Demski -
- Bryant Fong -
- Lawrence Guiheen -
We do not have data on ADMA Biologics' shareholders